Title: Docetaxel Versus Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
Abstract: Thank you for your interest and your comments on the recently published HORG (Hellenic Oncology Research Group) study. 1 Karampeazis A. Vamvakas L. Agelidou A. et al. Docetaxel vs. vinorelbine in elderly patients with advanced non–small-cell lung cancer: a Hellenic oncology research group randomized phase III study. Clin Lung Cancer. 2011; 12: 155-160 Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar Docetaxel vs. Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung CancerClinical Lung CancerVol. 13Issue 5PreviewWe read with great interest the May 2011 article by Karampeazis et al1 in Clinical Lung Cancer, “Docetaxel vs. vinorelbine in elderly patients with advanced non–small-cell lung cancer: a Hellenic Oncology Research Group randomized phase III study.” According to their study, the objective response rate and the median time to tumor progression was not different between the 2 treated groups of patients. However, the median overall survival tended to be longer than that of the vinorelbine-treated group. Full-Text PDF
Publication Year: 2012
Publication Date: 2012-09-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot